Combined modality therapy of gastric cancer Journal Article
| Authors: | Karpeh, M. S.; Kelsen, D. P. |
| Article Title: | Combined modality therapy of gastric cancer |
| Abstract: | Neoadjuvant chemotherapy in the treatment of gastric cancer has shown real promise in the recent years. Patients must be properly staged preoperatively with the intent of identifying those at substantial risk for treatment failure (i.e., T3 disease). Patients with less risk of recurrence can go straight to resection, whereas patients diagnosed with M1 disease will be offered more appropriate palliative measures. The problem of incomplete responses and chemoresistance may be addressed partly by current attempts to identify responding patients before treatment on the basis of molecular and biochemical studies. There is a clear need for novel treatment approaches and more effective systemic therapy. However, until sufficient data indicates that multimodality therapy improves outcome, these approaches should still be considered investigational. |
| Keywords: | cancer survival; survival rate; neutropenia; review; cancer recurrence; cisplatin; doxorubicin; fluorouracil; multimodality cancer therapy; patient selection; antineoplastic agents; preoperative care; chemotherapy, adjuvant; combined modality therapy; methotrexate; cancer staging; neoplasm staging; laparotomy; adenocarcinoma; neoplasm recurrence, local; etoposide; cause of death; folinic acid; forecasting; gastrectomy; stomach cancer; preoperative treatment; stomach neoplasms; endoscopic echography; intraperitoneal drug administration; sodium thiosulfate; humans; human |
| Journal Title: | Surgical Oncology Clinics of North America |
| Volume: | 6 |
| Issue: | 4 |
| ISSN: | 1055-3207 |
| Publisher: | Elsevier Inc. |
| Date Published: | 1997-10-01 |
| Start Page: | 741 |
| End Page: | 747 |
| Language: | English |
| PUBMED: | 9309091 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 17 March 2017 -- Source: Scopus |
Citation Impact
Related MSK Work